Chemical peels using either alpha-hydroxy acid or beta-hydroxy acid are both highly effective in treating mild to moderately severe facial acne, researchers at the Saint Louis University School of Medicine have found – the first study to compare the two different types of acid peels as therapies for the skin disorder.
Peels using beta-hydroxy acid (or BHA) had slightly fewer side effects and results that lasted a bit longer than did peels using alpha-hydroxy acid (or AHA), the study found. But overall, both types of treatments were similarly effective in reducing lesions caused by acne vulgaris, the medical term for common facial acne, which affects some 85 percent of all people 12 to 24 years old.
“This is good news for the millions of Americans who suffer from mild to moderately severe facial acne,” said Dee Anna Glaser, M.D., vice chair and professor of dermatology at the Saint Louis University School of Medicine. “This provides more options for patients and doctors to chose from when it comes to tailoring a treatment program for each individual.”
The research is published in the current edition of Dermatologic Surgery (
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1524-4725.2007.34007.x).
AHA (which is also called glycolic acid) and BHA (also called salicylic acid) are frequently used by physicians to induce light skin peels, which help treat fine lines and wrinkles, acne and uneven texture and coloration. The peel removes a very thin layer of skin, which in turn promotes the growth of new, smoother skin.
Both types of acid are derived from organic compounds. AHA has the same active ingredient that’s found in sugar cane juice, sour milk and tomato juice, while BHA is derived from salicin, which is closely related to the active ingredient in aspirin.
The study involved 20 patients with moderate to severe facial acne. Their average age was 24 years; 13 were women. Each was treated with a chemical peel every other week for six weeks, with follow-up visits one month and two months after the last treatment.
Each treatment involved applying alpha-hydroxy acid to one side of the face and beta-hydroxy acid to the other side. Neither the patient nor the person who later evaluated them were aware which side of the face had been treated with which acid.
The study found that both types of chemical peels significantly reduced acne lesions within two weeks of the first treatment, and patients continued to see a reduction in lesions through the first follow-up visit a month after the treatments had finished.
At the time of that first post-treatment visit, 94 percent of patients were judged to have had good or fair improvement in acne lesions on both sides of the face, as assessed by a blinded evaluator.
A month later, at the second post-treatment visit, 81 percent of the sides of the face treated with beta-hydroxy acid still showed good or fair improvement in acne lesions, compared with 75 percent of the sides of the face treated with alpha-hydroxy acid. However, the sides of the face treated with alpha-hydroxy acid had developed a few new lesions – though this was judged not to be significant.
In general, both types of acid peels yielded the same side effects, which typically decreased over the course of the treatments. The most common of these included redness, peeling and scaling – though with alpha-hydroxy acid, the degree of the peeling and scaling was judged to be greater.
Source: Saint Louis University
Related stories:
First do no harm? UH prof taking opposite approach to treat asthma
One month of tough breathing may help asthma sufferers breathe easier in the long run, according to research from one University of Houston professor.
How the drug isotretinoin zaps acne
The most potent drug available for the treatment of acne is 13-cis retinoic acid (13-cis RA; also known as isotretinoin); however, little is known about the mechanism by which it acts.
Regulation of the retinoic acid gradient in zebrafish embryos
Human embryos that get too much or too little retinoic acid, a derivative of Vitamin A, can develop into babies with birth defects. New research published this week in the open-access journal
PLoS Biology shows for the first time how embryonic cells may regulate levels of retinoic acid, providing insight into how retinoic acid signaling interacts with other key developmental signals to control development of the brain, limbs, and many other tissues in embryos.
Study shows how embryos regulate vitamin A derivatives
Human embryos that get too much or too little retinoic acid, a derivative of Vitamin A, can develop into babies with birth defects. New research at UC Irvine shows for the first time how embryonic cells may regulate levels of retinoic acid, giving scientists insight into how it acts as a signal between cells to control development of the brain, limbs and many other tissues in embryos.
Cancer researchers add spice to research against rare neuromuscular disease
Scientists who focus on the molecular signaling that underlies prostate cancer have discovered a compound that shows promise against a debilitating neurodegenerative condition known as Kennedy's disease, which is caused by a mutant gene. Currently there is no treatment for the inherited disorder, which resembles a slowly progressive form of Lou Gehrig's disease and affects only men.
Probing Question: Can steroids enhance athletic performance?
On May 28, baseball's Barry Bonds launched his 715th home run a whopping 455 feet to pass Babe Ruth as the No. 2 home run slugger of all time. But allegations of steroid use have caused many fans to turn their backs on the prolific hitter's accomplishment. While we may never know whether Bonds used steroids, the controversy still invites the question, "Can steroids really enhance athletic performance?"
Sensitive nanowire disease detectors made by Yale scientists
Yale scientists have created nanowire sensors coupled with simple microprocessor electronics that are both sensitive and specific enough to be used for point-of-care (POC) disease detection, according to a report in
Nano Letters.
A new explosive: Melt-castable nitrate ester with high explosive energy
Since the discovery of nitroglycerin in 1846, the nitrate ester group of compounds has been known for its explosive properties. A whole series of other nitrate esters have been subsequently put to use as explosives and fuels. A research team led by David E. Chavez at Los Alamos National Laboratory (USA) has now developed a novel tetranitrate ester. As reported in the journal
Angewandte Chemie, the compound has a particularly interesting characteristic profile: it is solid at room temperature, is a highly powerful explosive, and can be melt-cast into the desired shape.